Dynavax Technologies Corporation (DVAX)

Oncology Corporate Profile

Stock Performance

21.1000
0.6000

3 Month Stock History Chart

HQ Location

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Company Description

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine.

Website: http://www.dynavax.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)MelanomaI
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)Squamous cell cancer of the head and neck (SCCHN)I
SD-101 (+ anti IL-10)toll-like receptor 9 (TLR9)Various cancer typesIMerck
DV281toll-like receptor 9 (TLR9)Various cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.dynavax.com/

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/16/2017 06:18 pm

8/15/2017 12:18 pm

8/15/2017 12:18 pm

8/15/2017 12:18 pm

8/15/2017 12:18 pm

8/15/2017 12:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 pm

8/9/2017 06:18 am

8/9/2017 06:18 am

8/9/2017 06:18 am

8/9/2017 06:18 am

8/8/2017 12:18 pm

8/4/2017 06:18 am

8/3/2017 12:18 pm

8/3/2017 06:18 am

8/3/2017 06:18 am

8/3/2017 06:18 am